Study links breast cancer resistance with timing of soy consumption

April 2, 2012

Studies exploring the relationship between soy consumption and breast cancer have been mixed, but new research introduces a new thought: Could women with breast cancer who began eating soy as an adult develop a tumor more resistant to treatment?

That's the suggestion of a new study in animal models that could provide important hints for women with who eat soy. The research from Georgetown Lombardi Comprehensive Cancer Center was reported today at the American Association for (AACR) Annual Meeting 2012.

For tumors that are sensitive to hormonal treatment (estrogen receptor and/or progesterone receptor positive), tamoxifen is often given after primary treatment to keep the cancer at bay. Unfortunately, many tumors become resistant to the tamoxifen --meaning the drug stops working and the cancer grows again.

In the new research conducted in the laboratories of Leena Hilakivi-Clarke, PhD and Robert Clarke, PhD, DSc, both professors of oncology at Georgetown Lombardi, researchers looked at the impact soy consumption might have on .

For the study, were fed soy isoflavone genistein (a estrogen-like compound in soy) at various points in their lifetime. At adulthood, all rats were exposed to a substance that triggered to develop and then given tamoxifen. The study groups were as follows: one group was never fed genistein until tamoxifen was started; a second group was fed genistein only in youth and not again until tamoxifen was started; a third group was fed genistein only as adults and continued after tamoxifen was given; and finally, a fourth group was fed genistein during youth and adulthood and continued after tamoxifen was given.

"Genistein intake in adult life which continues during tamoxifen treatment appears to make the tumors resistant to tamoxifen," explains Hilakivi-Clarke, the study's senior author. "However, if animals were fed genistein during childhood, and intake continues before and after tumors develop, the tumors are highly sensitive to the ," she explains.

"These results suggest that western women who started soy intake as adults, should stop if diagnosed with breast cancer," Clarke concludes.

The research was presented by the abstract's lead author Xiyuan Zhang, M.S. Other authors include Anni Warri, Ph.D., Idalia M. Cruz, and Katherine Cook, Ph.D.

Related Stories

Recommended for you

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.